Multiple Sclerosis Therapeutics Market Report 2025-2030

The global multiple sclerosis (MS) therapeutics market represents a dynamic and rapidly evolving segment of the pharmaceutical industry. According to our proprietary primary research and expert interviews, the market was valued at USD 30.2 billion in 2025 and is projected to reach USD 38.6 billion by 2030, expanding at a CAGR of 5.9%. This growth is driven by the increasing global prevalence of MS, which now affects over 2.9 million people worldwide, and the continuous innovation in disease-modifying therapies (DMTs).

North America dominates the market, accounting for 38.3% of global revenue in 2024, followed by Europe and Asia Pacific. The Asia Pacific region is anticipated to be the fastest-growing market, with a projected CAGR of 7.0%, fueled by improving healthcare infrastructure and rising awareness.

Key segments include immunosuppressants, which held the largest share of 60.5% by drug class in 2024, and injectable therapies, which accounted for 52.5% of the market by route of administration. However, oral DMTs are gaining traction due to their convenience and improved patient adherence.

• Rising Prevalence: The number of people living with MS has grown from 2.3 million in 2013 to 2.9 million in 2023, creating a larger patient pool requiring treatment.
• Advancements in DMTs: The development of high-efficacy therapies, such as monoclonal antibodies and BTK inhibitors, has revolutionized MS management, reducing relapse rates and slowing disability progression.
• Investment in R&D: Leading pharmaceutical companies are investing heavily in clinical trials, with a robust pipeline of over 50 investigational drugs targeting remyelination and neuroprotection.
• Favorable Regulatory Environment: Orphan drug designations and accelerated approval pathways have expedited the availability of novel therapies.

• High Treatment Costs: Annual therapy costs can exceed USD 100,000 per patient, limiting access, especially in developing nations.
• Stringent Regulatory Requirements: Regulatory bodies like the FDA and EMA demand extensive long-term safety and efficacy data, increasing development timelines and costs.
• Manufacturing Complexity: Biologics require sophisticated manufacturing processes and cold-chain logistics, posing supply chain risks.
• Competition from Biosimilars: The entry of biosimilars for older biologics is intensifying price competition, challenging premium-priced therapies.

Our research segments the market by drug class, route of administration, distribution channel, and disease type.

• Relapsing-Remitting MS (RRMS): Accounts for 70% of all MS cases and dominates the market.
• Secondary-Progressive MS (SPMS): Growing segment with high unmet need.
• Primary-Progressive MS (PPMS): Limited treatment options; represents a significant opportunity.

• Largest market, with the U.S. accounting for over 80% of regional revenue.
• High prevalence of MS, advanced healthcare infrastructure, and favorable reimbursement policies drive growth.
• Presence of leading pharmaceutical companies and robust pipeline.

• Second-largest market, with Germany, France, and the UK as key contributors.
• Stringent HTA assessments influence market access; cost-effectiveness is critical.
• Increasing adoption of oral DMTs.

• Fastest-growing region, with a CAGR of 7.0%.
• Rising prevalence due to environmental and lifestyle factors.
• Improving healthcare infrastructure and government initiatives to enhance access.
• Key markets: China, Japan, India, and South Korea.

• Moderate growth, driven by increasing awareness and improving diagnosis rates.
• Brazil and Mexico are the largest markets.
• Price sensitivity and limited reimbursement are challenges.

• Nascent market with significant unmet need.
• Increasing investment in healthcare infrastructure and rising awareness.
• Saudi Arabia, UAE, and South Africa are key markets.

The MS therapeutics market is highly concentrated, with the top five players accounting for approximately 70% of global revenue. Our analysis identifies the following strategic archetypes:

• Market Leaders: Companies with broad portfolios of DMTs, including monoclonal antibodies and oral therapies, leveraging strong neurologist networks.
• Innovators: Biotech firms focusing on novel mechanisms like BTK inhibitors and CD40L antagonists.
• Generic and Biosimilar Manufacturers: Emerging players driving price competition.

Key players are engaged in strategic collaborations, mergers, and acquisitions to expand their pipelines and geographic reach. For instance, recent partnerships aim to accelerate the development of remyelination therapies.

• 2024: MS Australia awarded 17 research grants totaling over USD 4.5 million to advance MS research.
• 2023: National Multiple Sclerosis Society allocated USD 4 million towards new research initiatives, part of an annual commitment of over USD 30 million.
• 2023: Tolebrutinib, a BTK inhibitor, demonstrated a 31% decrease in disease progression in progressive MS, marking a significant breakthrough.
• 2022: Bristol Myers Squibb published analyses showing early Zeposia use provided cognitive benefits for relapsing MS patients.
• Pipeline: Over 50 drugs are in clinical development, including remibrutinib, fenebrutinib, frexalimab, and CNM-Au8, targeting progressive forms of MS.

The production of MS therapeutics involves complex supply chains, particularly for biologics. Key considerations include:

• API Sourcing: Many active pharmaceutical ingredients are manufactured in Europe and Asia, with stringent quality requirements.
• Biologics Manufacturing: Monoclonal antibodies require mammalian cell culture facilities, which are capital-intensive and subject to capacity constraints.
• Cold Chain Logistics: Injectable biologics require temperature-controlled storage and transport, adding cost and risk.
• Regulatory Compliance: Manufacturers must adhere to cGMP standards, with frequent inspections by regulatory agencies.

To mitigate risks, companies are diversifying suppliers and investing in continuous manufacturing technologies.

• For Pharmaceutical Companies: Focus on developing oral and long-acting therapies with improved efficacy and safety profiles. Invest in precision medicine approaches using biomarkers.
• For Investors: Target innovative biotech firms with novel mechanisms, particularly in progressive MS. Consider partnerships with established players for commercialization.
• For Healthcare Providers: Stay updated on emerging therapies and clinical guidelines to optimize patient outcomes. Advocate for reimbursement policies that ensure access.
• For Policymakers: Support research funding and streamline regulatory pathways to accelerate innovation. Implement value-based pricing models to balance cost and access.